Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Biomarkers | Research

Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis

Authors: Viola Melone, Annamaria Salvati, Domenico Palumbo, Giorgio Giurato, Giovanni Nassa, Francesca Rizzo, Luigi Palo, Alessandro Giordano, Mariarosaria Incoronato, Mario Vitale, Caterina Mian, Immacolata Di Biase, Stefano Cristiano, Viviana Narciso, Monica Cantile, Annabella Di Mauro, Fabiana Tatangelo, Salvatore Tafuto, Roberta Modica, Claudia Pivonello, Marco Salvatore, Annamaria Colao, Alessandro Weisz, Roberta Tarallo

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Neuroendocrine neoplasms (NENs) represent a heterogeneous class of rare tumors with increasing incidence. They are characterized by the ability to secrete peptide hormones and biogenic amines but other reliable biomarkers are lacking, making diagnosis and identification of the primary site very challenging. While in some NENs, such as the pancreatic ones, next generation sequencing technologies allowed the identification of new molecular hallmarks, our knowledge of the molecular profile of NENs from other anatomical sites is still poor.

Methods

Starting from the concept that NENs from different organs may be clinically and genetically correlated, we applied a multi-omics approach by combining multigene panel testing, CGH-array, transcriptome and miRNome profiling and computational analyses, with the aim to highlight common molecular and functional signatures of gastroenteropancreatic (GEP)-NENs and medullary thyroid carcinomas (MTCs) that could aid diagnosis, prognosis and therapy.

Results

By comparing genomic and transcriptional profiles, ATM-dependent signaling emerged among the most significant pathways at multiple levels, involving gene variations and miRNA-mediated regulation, thus representing a novel putative druggable pathway in these cancer types. Moreover, a set of circulating miRNAs was also selected as possible diagnostic/prognostic biomarkers useful for clinical management of NENs.

Conclusions

These findings depict a complex molecular and functional landscape of NENs, shedding light on novel therapeutic targets and disease biomarkers to be exploited.
Appendix
Available only for authorised users
Literature
1.
3.
go back to reference Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.PubMedCrossRef Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.PubMedCrossRef
4.
go back to reference Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–86.PubMedPubMedCentralCrossRef Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–86.PubMedPubMedCentralCrossRef
5.
go back to reference Anlauf M, Garbrecht N, Bauersfeld J, Schmitt A, Henopp T, Komminoth P, et al. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch. 2007;451(Suppl 1):S29-38.PubMedCrossRef Anlauf M, Garbrecht N, Bauersfeld J, Schmitt A, Henopp T, Komminoth P, et al. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch. 2007;451(Suppl 1):S29-38.PubMedCrossRef
6.
go back to reference Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V, et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience. 2019;20:324–36.PubMedPubMedCentralCrossRef Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V, et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience. 2019;20:324–36.PubMedPubMedCentralCrossRef
7.
go back to reference Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.PubMedCrossRef Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.PubMedCrossRef
8.
go back to reference Dabelić N, Jukić T, Fröbe A. Medullary thyroid cancer—feature review and update on systemic treatment. Acta Clin Croat. 2020;59(Suppl 1):50–9.PubMedPubMedCentral Dabelić N, Jukić T, Fröbe A. Medullary thyroid cancer—feature review and update on systemic treatment. Acta Clin Croat. 2020;59(Suppl 1):50–9.PubMedPubMedCentral
9.
go back to reference Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4(1):64–71.PubMedCrossRef Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4(1):64–71.PubMedCrossRef
10.
go back to reference Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203.PubMedPubMedCentralCrossRef Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203.PubMedPubMedCentralCrossRef
11.
go back to reference Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71.PubMedCrossRef Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71.PubMedCrossRef
12.
go back to reference Stevenson M, Lines KE, Thakker RV. Molecular genetic studies of pancreatic neuroendocrine tumors: new therapeutic approaches. Endocrinol Metab Clin North Am. 2018;47(3):525–48.PubMedCrossRef Stevenson M, Lines KE, Thakker RV. Molecular genetic studies of pancreatic neuroendocrine tumors: new therapeutic approaches. Endocrinol Metab Clin North Am. 2018;47(3):525–48.PubMedCrossRef
13.
go back to reference Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45(12):1483–6.PubMedPubMedCentralCrossRef Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45(12):1483–6.PubMedPubMedCentralCrossRef
14.
go back to reference Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, et al. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest. 2013;123(6):2502–8.PubMedPubMedCentralCrossRef Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, et al. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest. 2013;123(6):2502–8.PubMedPubMedCentralCrossRef
15.
go back to reference Saghaeiannejad Esfahani H, Vela CM, Chauhan A. Prevalence of TP-53/Rb-1 co-mutation in large cell neuroendocrine carcinoma. Front Oncol. 2021;11: 653153.PubMedPubMedCentralCrossRef Saghaeiannejad Esfahani H, Vela CM, Chauhan A. Prevalence of TP-53/Rb-1 co-mutation in large cell neuroendocrine carcinoma. Front Oncol. 2021;11: 653153.PubMedPubMedCentralCrossRef
16.
go back to reference Jesinghaus M, Konukiewitz B, Keller G, Kloor M, Steiger K, Reiche M, et al. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Mod Pathol. 2017;30(4):610–9.PubMedCrossRef Jesinghaus M, Konukiewitz B, Keller G, Kloor M, Steiger K, Reiche M, et al. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Mod Pathol. 2017;30(4):610–9.PubMedCrossRef
18.
go back to reference Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471–87.PubMedCrossRef Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471–87.PubMedCrossRef
19.
go back to reference Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.PubMedPubMedCentralCrossRef Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.PubMedPubMedCentralCrossRef
20.
go back to reference Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010;145(3):276–80.PubMedCrossRef Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010;145(3):276–80.PubMedCrossRef
21.
go back to reference De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, et al. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. J Transl Med. 2016;14(1):113.PubMedPubMedCentralCrossRef De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, et al. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. J Transl Med. 2016;14(1):113.PubMedPubMedCentralCrossRef
23.
go back to reference Bartz-Kurycki MA, Oluwo OE, Morris-Wiseman LF. Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis. Ther Adv Endocrinol Metab. 2021;12:20420188211049612.PubMedPubMedCentralCrossRef Bartz-Kurycki MA, Oluwo OE, Morris-Wiseman LF. Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis. Ther Adv Endocrinol Metab. 2021;12:20420188211049612.PubMedPubMedCentralCrossRef
24.
go back to reference Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007;14(2):473–82.PubMedCrossRef Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007;14(2):473–82.PubMedCrossRef
25.
go back to reference Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–12.PubMedCrossRef Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–12.PubMedCrossRef
27.
go back to reference Klimstra DS. Pathologic classification of neuroendocrine neoplasms. Hematol Oncol Clin North Am. 2016;30(1):1–19.PubMedCrossRef Klimstra DS. Pathologic classification of neuroendocrine neoplasms. Hematol Oncol Clin North Am. 2016;30(1):1–19.PubMedCrossRef
28.
go back to reference Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, et al. Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32–45.PubMedCrossRef Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, et al. Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32–45.PubMedCrossRef
29.
go back to reference Faggiano A, Lo Calzo F, Pizza G, Modica R, Colao A. The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf. 2017;16(10):1149–61.PubMedCrossRef Faggiano A, Lo Calzo F, Pizza G, Modica R, Colao A. The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf. 2017;16(10):1149–61.PubMedCrossRef
30.
go back to reference Faggiano A, Di Maio S, Mocerino C, Ottaviano M, De Divitiis C, Guarnotta V, et al. Therapeutic sequences in patients with grade 1–2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019;66(2):417–24.PubMedCrossRef Faggiano A, Di Maio S, Mocerino C, Ottaviano M, De Divitiis C, Guarnotta V, et al. Therapeutic sequences in patients with grade 1–2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019;66(2):417–24.PubMedCrossRef
31.
go back to reference Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, et al. The UCSC genome browser database: update 2006. Nucleic Acids Res. 2006;34(Database issue):D590-8.PubMedCrossRef Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, et al. The UCSC genome browser database: update 2006. Nucleic Acids Res. 2006;34(Database issue):D590-8.PubMedCrossRef
32.
go back to reference Chang X, Wang K. wANNOVAR: annotating genetic variants for personal genomes via the web. J Med Genet. 2012;49(7):433–6.PubMedCrossRef Chang X, Wang K. wANNOVAR: annotating genetic variants for personal genomes via the web. J Med Genet. 2012;49(7):433–6.PubMedCrossRef
33.
go back to reference Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.PubMedPubMedCentralCrossRef Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.PubMedPubMedCentralCrossRef
34.
go back to reference Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639–45.PubMedPubMedCentralCrossRef Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639–45.PubMedPubMedCentralCrossRef
35.
go back to reference Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010.
37.
go back to reference Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.PubMedCrossRef Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.PubMedCrossRef
38.
go back to reference Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923–30.PubMedCrossRef Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923–30.PubMedCrossRef
40.
go back to reference Haas BJ, Dobin A, Stransky N, Li B, Yang X, Tickle T, et al. STAR-fusion: fast and accurate fusion transcript detection from RNA-Seq. bioRxiv. 2017;34:533. Haas BJ, Dobin A, Stransky N, Li B, Yang X, Tickle T, et al. STAR-fusion: fast and accurate fusion transcript detection from RNA-Seq. bioRxiv. 2017;34:533.
41.
go back to reference Panero R, Rinaldi A, Memoli D, Nassa G, Ravo M, Rizzo F, et al. iSmaRT: a toolkit for a comprehensive analysis of small RNA-Seq data. Bioinformatics. 2017;33(24):4050.PubMedCrossRef Panero R, Rinaldi A, Memoli D, Nassa G, Ravo M, Rizzo F, et al. iSmaRT: a toolkit for a comprehensive analysis of small RNA-Seq data. Bioinformatics. 2017;33(24):4050.PubMedCrossRef
42.
43.
go back to reference Walter W, Sánchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31(17):2912–4.PubMedCrossRef Walter W, Sánchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31(17):2912–4.PubMedCrossRef
44.
go back to reference Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef
45.
go back to reference Lloyd R, Osamura R, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. Lyon: IARC Press; 2017. Lloyd R, Osamura R, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. Lyon: IARC Press; 2017.
46.
go back to reference Klimstra D, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours Editorial Board, editor. WHO Classification of tumours: digestive system tumours. Lyon: International Agency for Research on Cancer; 2019. p. 16. Klimstra D, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours Editorial Board, editor. WHO Classification of tumours: digestive system tumours. Lyon: International Agency for Research on Cancer; 2019. p. 16.
47.
go back to reference Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62(Suppl 1):33–8.PubMedCrossRef Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62(Suppl 1):33–8.PubMedCrossRef
48.
go back to reference Blind E, Schmidt-Gayk H, Sinn HP, O’Connor DT, Raue F. Chromogranin A as tumor marker in medullary thyroid carcinoma. Thyroid. 1992;2(1):5–10.PubMedCrossRef Blind E, Schmidt-Gayk H, Sinn HP, O’Connor DT, Raue F. Chromogranin A as tumor marker in medullary thyroid carcinoma. Thyroid. 1992;2(1):5–10.PubMedCrossRef
50.
go back to reference Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature. 2003;421(6926):961–6.PubMedCrossRef Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature. 2003;421(6926):961–6.PubMedCrossRef
51.
go back to reference Nakanishi M, Ozaki T, Yamamoto H, Hanamoto T, Kikuchi H, Furuya K, et al. NFBD1/MDC1 associates with p53 and regulates its function at the crossroad between cell survival and death in response to DNA damage. J Biol Chem. 2007;282(31):22993–3004.PubMedCrossRef Nakanishi M, Ozaki T, Yamamoto H, Hanamoto T, Kikuchi H, Furuya K, et al. NFBD1/MDC1 associates with p53 and regulates its function at the crossroad between cell survival and death in response to DNA damage. J Biol Chem. 2007;282(31):22993–3004.PubMedCrossRef
54.
go back to reference Cavalcanti E, Galleggiante V, Coletta S, Stasi E, Chieppa M, Armentano R, et al. Altered miRNAs expression correlates with gastroenteropancreatic neuroendocrine tumors grades. Front Oncol. 2020;10:1187.PubMedPubMedCentralCrossRef Cavalcanti E, Galleggiante V, Coletta S, Stasi E, Chieppa M, Armentano R, et al. Altered miRNAs expression correlates with gastroenteropancreatic neuroendocrine tumors grades. Front Oncol. 2020;10:1187.PubMedPubMedCentralCrossRef
55.
go back to reference Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012;10:42.PubMedPubMedCentralCrossRef Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012;10:42.PubMedPubMedCentralCrossRef
56.
go back to reference Chen WY, Wen YC, Lin SR, Yeh HL, Jiang KC, Chen WH, et al. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. Commun Biol. 2021;4(1):22.PubMedPubMedCentralCrossRef Chen WY, Wen YC, Lin SR, Yeh HL, Jiang KC, Chen WH, et al. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. Commun Biol. 2021;4(1):22.PubMedPubMedCentralCrossRef
57.
go back to reference Takacova M, Bullova P, Simko V, Skvarkova L, Poturnajova M, Feketeova L, et al. Expression pattern of carbonic anhydrase IX in medullary thyroid carcinoma supports a role for RET-mediated activation of the HIF pathway. Am J Pathol. 2014;184(4):953–65.PubMedCrossRef Takacova M, Bullova P, Simko V, Skvarkova L, Poturnajova M, Feketeova L, et al. Expression pattern of carbonic anhydrase IX in medullary thyroid carcinoma supports a role for RET-mediated activation of the HIF pathway. Am J Pathol. 2014;184(4):953–65.PubMedCrossRef
58.
go back to reference Sun W, Wu W, Wang Q, Yao Q, Feng Q, Wang Y, et al. Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. J Transl Med. 2022;20(1):114.PubMedPubMedCentralCrossRef Sun W, Wu W, Wang Q, Yao Q, Feng Q, Wang Y, et al. Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. J Transl Med. 2022;20(1):114.PubMedPubMedCentralCrossRef
59.
go back to reference Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013;31(3):365–72.PubMedCrossRef Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013;31(3):365–72.PubMedCrossRef
61.
go back to reference Panarelli N, Tyryshkin K, Wong JJM, Majewski A, Yang X, Scognamiglio T, et al. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. Endocr Relat Cancer. 2019;26(1):47–57.PubMedCrossRef Panarelli N, Tyryshkin K, Wong JJM, Majewski A, Yang X, Scognamiglio T, et al. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. Endocr Relat Cancer. 2019;26(1):47–57.PubMedCrossRef
62.
go back to reference Colao A, de Nigris F, Modica R, Napoli C. Clinical epigenetics of neuroendocrine tumors: the road ahead. Front Endocrinol. 2020;11: 604341.CrossRef Colao A, de Nigris F, Modica R, Napoli C. Clinical epigenetics of neuroendocrine tumors: the road ahead. Front Endocrinol. 2020;11: 604341.CrossRef
63.
go back to reference Chiacchiarini M, Trocchianesi S, Besharat ZM, Po A, Ferretti E. Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer. Pharmacol Ther. 2021;219: 107708.PubMedCrossRef Chiacchiarini M, Trocchianesi S, Besharat ZM, Po A, Ferretti E. Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer. Pharmacol Ther. 2021;219: 107708.PubMedCrossRef
64.
go back to reference Romeo P, Colombo C, Granata R, Calareso G, Gualeni AV, Dugo M, et al. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. Endocr Relat Cancer. 2018;25(3):217–31.PubMedCrossRef Romeo P, Colombo C, Granata R, Calareso G, Gualeni AV, Dugo M, et al. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. Endocr Relat Cancer. 2018;25(3):217–31.PubMedCrossRef
65.
go back to reference Shabani N, Razaviyan J, Paryan M, Tavangar SM, Azizi F, Mohammadi-Yeganeh S, et al. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC. Hum Pathol. 2018;79:212–21.PubMedCrossRef Shabani N, Razaviyan J, Paryan M, Tavangar SM, Azizi F, Mohammadi-Yeganeh S, et al. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC. Hum Pathol. 2018;79:212–21.PubMedCrossRef
66.
go back to reference Yan J, Yu S, Jia C, Li M, Chen J. Molecular subtyping in pancreatic neuroendocrine neoplasms: new insights into clinical, pathological unmet needs and challenges. Biochim Biophys Acta Rev Cancer. 2020;1874(1): 188367.PubMedCrossRef Yan J, Yu S, Jia C, Li M, Chen J. Molecular subtyping in pancreatic neuroendocrine neoplasms: new insights into clinical, pathological unmet needs and challenges. Biochim Biophys Acta Rev Cancer. 2020;1874(1): 188367.PubMedCrossRef
67.
go back to reference Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98(2):E364–9.PubMedCrossRef Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98(2):E364–9.PubMedCrossRef
68.
go back to reference Coster G, Goldberg M. The cellular response to DNA damage: a focus on MDC1 and its interacting proteins. Nucleus. 2010;1(2):166–78.PubMedCrossRef Coster G, Goldberg M. The cellular response to DNA damage: a focus on MDC1 and its interacting proteins. Nucleus. 2010;1(2):166–78.PubMedCrossRef
69.
go back to reference Kao J, Milano MT, Javaheri A, Garofalo MC, Chmura SJ, Weichselbaum RR, et al. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006;6(3):197–205.PubMedCrossRef Kao J, Milano MT, Javaheri A, Garofalo MC, Chmura SJ, Weichselbaum RR, et al. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006;6(3):197–205.PubMedCrossRef
71.
go back to reference Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis. 2017;8(8): e3004.PubMedPubMedCentralCrossRef Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis. 2017;8(8): e3004.PubMedPubMedCentralCrossRef
72.
go back to reference Okuyama H, Ikeda M, Okusaka T, Furukawa M, Ohkawa S, Hosokawa A, et al. A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). Neuroendocrinology. 2020;110(11–12):988–93.PubMedCrossRef Okuyama H, Ikeda M, Okusaka T, Furukawa M, Ohkawa S, Hosokawa A, et al. A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). Neuroendocrinology. 2020;110(11–12):988–93.PubMedCrossRef
73.
go back to reference Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, et al. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS ONE. 2019;14(9): e0221994.PubMedPubMedCentralCrossRef Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, et al. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS ONE. 2019;14(9): e0221994.PubMedPubMedCentralCrossRef
74.
go back to reference Faggiano A, Malandrino P, Modica R, Agrimi D, Aversano M, Bassi V, et al. Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature. Oncologist. 2016;21(7):875–86.PubMedPubMedCentralCrossRef Faggiano A, Malandrino P, Modica R, Agrimi D, Aversano M, Bassi V, et al. Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature. Oncologist. 2016;21(7):875–86.PubMedPubMedCentralCrossRef
75.
go back to reference Cam H, Easton JB, High A, Houghton PJ. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell. 2010;40(4):509–20.PubMedPubMedCentralCrossRef Cam H, Easton JB, High A, Houghton PJ. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell. 2010;40(4):509–20.PubMedPubMedCentralCrossRef
76.
go back to reference Alexander A, Cai SL, Kim J, Nanez A, Sahin M, MacLean KH, et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA. 2010;107(9):4153–8.PubMedPubMedCentralCrossRef Alexander A, Cai SL, Kim J, Nanez A, Sahin M, MacLean KH, et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA. 2010;107(9):4153–8.PubMedPubMedCentralCrossRef
78.
go back to reference Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018;4(6):eaat1719.PubMedPubMedCentralCrossRef Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018;4(6):eaat1719.PubMedPubMedCentralCrossRef
80.
go back to reference Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, et al. The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5-c]quinolin-2-one). J Med Chem. 2018;61(9):3823–41.PubMedCrossRef Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, et al. The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5-c]quinolin-2-one). J Med Chem. 2018;61(9):3823–41.PubMedCrossRef
Metadata
Title
Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis
Authors
Viola Melone
Annamaria Salvati
Domenico Palumbo
Giorgio Giurato
Giovanni Nassa
Francesca Rizzo
Luigi Palo
Alessandro Giordano
Mariarosaria Incoronato
Mario Vitale
Caterina Mian
Immacolata Di Biase
Stefano Cristiano
Viviana Narciso
Monica Cantile
Annabella Di Mauro
Fabiana Tatangelo
Salvatore Tafuto
Roberta Modica
Claudia Pivonello
Marco Salvatore
Annamaria Colao
Alessandro Weisz
Roberta Tarallo
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Biomarkers
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03511-7

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.